BIOCHINA 2025 Announces Esteemed Expert Committee to Guide International Convention in Suzhou
November 28, 2024 – Biotechnology – BIOCHINA, China, Networking, event
28 November 2024 –Shanghai, China – BIOCHINA, Asia’s leading platform for biotechnology and pharmaceutical innovation, proudly announces the appointment of an Expert Committee for the upcoming BIOCHINA 2025 International Convention. Set to take place from March 13-15, 2025, in Suzhou, China, the event will bring together global industry leaders, innovators, and experts for three days of insight, collaboration, and advancement in biotechnology.
BIOCHINA 2025 aims to create a robust environment for discussing breakthroughs, fostering partnerships, and accelerating the bio-industry’s growth. The Expert Committee, composed of renowned scientists, executives, and leaders from prestigious institutions and industry decision makers, will play an instrumental role in shaping the event’s agenda and fostering cross-border collaborations.
Meet the BIOCHINA 2025 Expert Committee:
- Honorary Chairman: Kaixian Chen, Academician of the Chinese Academy of Sciences
- General Chairman: Piaoyang Sun, Chairman of Hengrui Pharma
Expert Committee Members:
- Zhihong Chen, CEO, Curon Biopharmaceutical (Shanghai) Ltd.
- Dong Chen, Academician, Chinese Academy of Sciences; Dean, Medical School of Westlake University
- Aimin Hui, Chair & CEO, EnCureGen Pharma; Professor, State Key Laboratory of Respiratory Diseases
- Linong Ji, Director, Department of Endocrinology and Metabolism, Peking University People’s Hospital
- Ning Li, Chairman, TopAlliance Biosciences
- Zonghai Li, Chairman & CEO, CARsgen
- Yong Jun Liu, Executive President, President Global R&D, CSPC PHARMA
- Shen Lin, Director, Department of Gastrointestinal Oncology, Peking University Cancer Hospital
- Su Bing, Wang Kuan-Cheng Chair Professor, Shanghai Jiao Tong University; Director, Shanghai Institute of Immunology
- Weikang Tao, Corp VP and President of Global R&D of Innovative Medicines, Qilu Pharmaceutical Group
- Huji Xu, Professor, Shanghai Changzheng Hospital
- Lianshan Zhang, Board Director & Vice President, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Caicun Zhou, Director, Shanghai East Hospital
- John Zhu, Founder & CEO, Duality Biologics
Guiding BIOCHINA’s Vision for 2025 and Beyond
This committee will leverage their expertise across various biotech disciplines—including immunology, oncology, endocrinology, and innovative drug development—to guide BIOCHINA 2025’s program and content. Their insights will ensure that the event remains a premier platform for breakthroughs in bioprocessing, drug discovery, and international partnerships.
Join Us in Suzhou
BIOCHINA 2025 invites nearly 3000 of Chinese biotech companies, researchers, and investors worldwide to participate, connect with these thought leaders, and explore new opportunities in the global bio-industry landscape. For further information on registration and event details, visit BIOCHINA’s official website or contact us at jessieyu@enmore.com.
About BIOCHINA: BIOCHINA is a premier international platform dedicated to fostering communication and collaboration within the biotechnology sector. Serving over 3,000 biotech companies in China and beyond, BIOCHINA connects innovators, accelerates breakthroughs, and empowers the global bio-industry. Visit: https://event.morebio.cn/ievent-sign/pc/#/registerationPage/en-us/150456?platformId=3&bizId=3&invitationCodeId=493924&personal=true
